Search research articles
Contact Us
Filters
Showing results (21-30 of 46) with videos related to
Page
of 5
Sort By:
Zentralblatt Fur Bakteriologie : International Journal of Medical Microbiology
|
June 1, 1991
Intestinal worm burden and serum cholesterol or lipid concentration in a Shipibo population (Peru)
U Wiedermann, H Stemberger, E Unfried, et al.
Allergy
|
June 24, 2006
Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1
C Daniel, A Repa, C Wild, et al.
International Archives of Allergy and Immunology
|
April 18, 2001
Mucosal tolerance induction with hypoallergenic molecules in a murine model of allergic asthma
U Wiedermann, U Herz, S Vrtala, et al.
Folia Microbiologica
|
May 29, 2026
Gnotobiotic mouse models as tools for dissecting the role of the microbiota in allergy: contributions from the laboratory of gnotobiology in Nový Hrádek
I Schabussova, H Kozakova, A Inic-Kanada, et al.
Mucosal Immunology
|
September 23, 2018
E. coli Nissle 1917 is a safe mucosal delivery vector for a birch-grass pollen chimera to prevent allergic poly-sensitization
P J Sarate, S Heinl, S Poiret, et al.
Mucosal Immunology
|
November 3, 2018
Correction: E. coli Nissle 1917 is a safe mucosal delivery vector for a birch-grass pollen chimera to prevent allergic poly-sensitization
P J Sarate, S Heinl, S Poiret, et al.
Clinical and Experimental Immunology
|
March 1, 1997
Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1
L Bauer, B Bohle, B Jahn-Schmid, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
May 11, 2002
Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice
B Winkler, K Baier, S Wagner, et al.
Allergy
|
December 13, 2006
A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities
C Wild, M Wallner, K Hufnagl, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
October 14, 2004
Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination
M Focke, B Linhart, A Hartl, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 46) with videos related to
Sort By:
Page
of 5
Zentralblatt Fur Bakteriologie : International Journal of Medical Microbiology
|
June 1, 1991
Intestinal worm burden and serum cholesterol or lipid concentration in a Shipibo population (Peru)
U Wiedermann, H Stemberger, E Unfried, et al.
Allergy
|
June 24, 2006
Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1
C Daniel, A Repa, C Wild, et al.
International Archives of Allergy and Immunology
|
April 18, 2001
Mucosal tolerance induction with hypoallergenic molecules in a murine model of allergic asthma
U Wiedermann, U Herz, S Vrtala, et al.
Folia Microbiologica
|
May 29, 2026
Gnotobiotic mouse models as tools for dissecting the role of the microbiota in allergy: contributions from the laboratory of gnotobiology in Nový Hrádek
I Schabussova, H Kozakova, A Inic-Kanada, et al.
Mucosal Immunology
|
September 23, 2018
E. coli Nissle 1917 is a safe mucosal delivery vector for a birch-grass pollen chimera to prevent allergic poly-sensitization
P J Sarate, S Heinl, S Poiret, et al.
Mucosal Immunology
|
November 3, 2018
Correction: E. coli Nissle 1917 is a safe mucosal delivery vector for a birch-grass pollen chimera to prevent allergic poly-sensitization
P J Sarate, S Heinl, S Poiret, et al.
Clinical and Experimental Immunology
|
March 1, 1997
Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1
L Bauer, B Bohle, B Jahn-Schmid, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
May 11, 2002
Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice
B Winkler, K Baier, S Wagner, et al.
Allergy
|
December 13, 2006
A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities
C Wild, M Wallner, K Hufnagl, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
October 14, 2004
Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination
M Focke, B Linhart, A Hartl, et al.
Page
of 5